

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information****1. NAME OF THE MEDICINAL PRODUCT**

CO-VIZARTAN® 50 mg/12.5 mg film-coated tablets.

2. QUALITATIVE AND QUANTITATIVE COMPOSITIONActive ingredients

Losartan (DCI) Potassium	50,00 mg
Hydrochlorothiazide	12,50 mg

Excipients:**Core:**

Microcrystalline cellulose	101,75 mg
Pregelatinized starch	10,00 mg
Lactose	75,00 mg
Magnesium stearate	0,75 mg

Film coating:

Opadray yellow 20A52067*	5,00 mg
Eau purifiée**	q.s

For one Film-coated tablets

* Including 20% of overages.

** do not appear in the finished product.

Excipients with known effects: Lactose.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film coated tablets.

Yellow, circular, biconvex film-coated tablet plain on both sides.

4. CLINICAL PARTICULARS**4.1 Therapeutic indications**

CO-VIZARTAN® is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide alone.

4.2 Posology and method of administration**Posology**Hypertension

Losartan potassium and hydrochlorothiazide is not for use as initial therapy, but in patients whose blood pressure is not adequately controlled by losartan potassium or hydrochlorothiazide alone.

Dose titration with the individual components (losartan potassium and hydrochlorothiazide) is recommended.

When clinically appropriate, direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled.

The usual maintenance dose is one tablet of CO-VIZARTAN® 50 mg/12.5 mg (Losartan potassium/ Hydrochlorothiazide 50mg/12.5mg) once daily.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information**

For patients who do not respond adequately to CO-VIZARTAN® 50 mg/12.5 mg, the dosage may be increased to two tablets of CO-VIZARTAN® daily.

The maximum dose is two tablets of CO-VIZARTAN® once daily.

In general, the antihypertensive effect is attained within three to four weeks after initiation of therapy.

Use in patients with renal impairment and haemodialysis patients:

No initial dosage adjustment is necessary in patients with moderate renal impairment (i.e. creatinine clearance 30-50 ml/min). Losartan potassium and Hydrochlorothiazide tablets are not recommended for haemodialysis patients.

Losartan potassium/ Hydrochlorothiazide tablets must not be used in patients with severe renal impairment (i.e. creatinine clearance <30 ml/min) (see section 4.3).

Use in patients with intravascular volume depletion:

Volume and/or sodium depletion should be corrected prior to administration of Losartan potassium/Hydrochlorothiazide tablets.

Use in patients with hepatic impairment

Losartan potassium/ Hydrochlorothiazide is contraindicated in patients with severe hepatic impairment (see section 4.3.).

Use in the elderly

Patients over 75 years: Dosage adjustment is not usually necessary for the elderly.

Use in children and adolescents (< 18 years)

There is no experience in children and adolescents. Therefore, Losartan potassium/ Hydrochlorothiazide should not be administered to children and adolescents.

Method of administration

CO-VIZARTAN® may be administered with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1).

CO-VIZARTAN® tablets should be swallowed with a glass of water.

CO-VIZARTAN® may be administered with or without food.

4.3 Contraindications

- Hypersensitivity to losartan, sulphonamide-derived substances (as hydrochlorothiazide) or to any of the excipients (see section 6.1),
- Therapy resistant hypokalaemia or hypercalcaemia,
- Severe hepatic impairment, cholestasis or biliary obstructive disorders,
- Refractory hyponatraemia,
- Symptomatic hyperuricaemia or gout,
- The 2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6),
- Severe renal impairment (i.e. creatinine clearance <30 ml/min),
- Anuria,
- The concomitant use of CO-VIZARTAN® with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²) (see sections 4.5 and 5.1),
- Lifetime contraindication: history of bradykinic angioedema under treatment with ACE inhibitor or ARA II.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information****4.4 Special warnings and precautions for use****Losartan:****Angioedema**

Patients with a history of angioedema (swelling of the face, lips, throat, and/or tongue) should be closely monitored (see section 4.8).

Hypotension and Intravascular volume depletion

Symptomatic hypotension, especially after the first dose, may occur in patients who are volume- and/or sodium-depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of CO-VIZARTAN® (see sections 4.2 and 4.3).

Electrolyte imbalances

Electrolyte imbalances are common in patients with renal impairment, with or without diabetes and should be addressed. Therefore, the plasma concentrations of potassium and creatinine clearance values should be closely monitored; especially patients with heart failure and a creatinine clearance between 30-50 ml/ min should be closely monitored.

The concomitant use of potassium sparing diuretics, potassium supplements and potassium containing salt substitutes with losartan potassium/hydrochlorothiazide is not recommended (see section 4.5).

Liver function impairment

Based on pharmacokinetic data which demonstrate significantly increased plasma concentrations of losartan potassium in cirrhotic patients, CO-VIZARTAN® should be used with caution in patients with a history of mild to moderate hepatic impairment.

There is no therapeutic experience with losartan potassium in patients with severe hepatic impairment. Therefore, CO-VIZARTAN® is contraindicated in patients with severe hepatic impairment (see sections 4.2, 4.3 and 5.2).

Renal function impairment

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function, including renal failure, have been reported (in particular, in patients whose renal function is dependent on the renin angiotensin-aldosterone system, such as those with severe cardiac insufficiency or pre-existing renal dysfunction).

As with other drugs that affect the renin-angiotensin-aldosterone system, increases in blood urea and serum creatinine have also been reported in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney; these changes in renal function may be reversible upon discontinuation of therapy.

Losartan should be used with caution in these patients.

Renal transplantation

There is no experience in patients with recent kidney transplantation.

Primary hyperaldosteronism

Patients with primary aldosteronism generally will not respond to antihypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of CO-VIZARTAN® tablet is not recommended.

Coronary heart disease and cerebrovascular disease

As with any antihypertensive agents, excessive blood pressure decrease in patients with ischaemic cardiovascular and cerebrovascular disease could result in a myocardial infarction or stroke.

Heart failure

In patients with heart failure, with or without renal impairment, there is - as with other drugs acting on the renin-angiotensin system - a risk of severe arterial hypotension and (often acute) renal impairment.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information***Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy*

As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

Ethnic differences

As observed for angiotensin converting enzyme inhibitors, losartan potassium and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low- renin states in the black hypertensive population.

Bradykinic angioedema

Bradykinic angioedema has been reported in patients treated with ACE inhibitors (ACE inhibitors: Benazepril, Captopril, Cilazapril, Delapril, Enalapril, Fosinopril, Lisinopril, Perindopril, Tanatril, Trandolapril, Zofenopril) but also receptor antagonists. angiotensin II (ARA II: Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan) and gliptins (Sitagliptin, Vildagliptin, Linagliptin, Alogliptin, Saxagliptin).

These angioedemas can have serious consequences.

Healthcare professionals and patients are advised to be particularly attentive to the signs suggestive of this type of angioedema when taking these medications.

Bradykinic angioedema occurs due to a lack of bradykinin degradation. They are either of hereditary origin (associated or not with a C1 inhibitor deficiency), or of medicinal origin by inhibition of enzymes which degrade bradykinin, in particular: the converting enzyme for ACE or ARA II (sartans) and dipeptidylpeptidase for gliptins.

These angioedemas (AE) most often present in the form of edema of the hypodermis, non-pruritic, of sudden onset, located mainly in the face, tongue or upper airways (30% laryngeal involvement if AE of the face) in a patient treated with ACE inhibitor or more rarely with sartan. AE that is isolated and therefore not associated with urticaria or other manifestations suggestive of anaphylaxis develops over a few hours or several days.

More distorting but much less frequent than IgE-mediated angioedema, of which it represents the differential diagnosis, bradykinic AE can also be localized to the digestive mucosa and present in the form of abdominal pain of varying intensity. Unlike AE by histamine release, it regresses spontaneously despite the continuation of the drug in question, which often leads to not mentioning the drug hypothesis. Unlike hereditary or acquired forms of bradykin angioedema, the levels of inhibitory C1 (weight or functional) and C4 are normal.

The onset times range from a few hours to several years after starting the medication and the attacks can become more and more frequent and/or more and more severe, always with a predilection for the ENT sector. In some patients a recurrence is possible within 6 months following stopping the ACE inhibitor or sartan, which can complicate the diagnosis.

The combination of an ACE inhibitor or a sartan with certain medications that increase the concentration of bradykinin, notably inhibitors of dipeptidyl peptidase IV (gliptin family), increases the risk of developing bradykin angioedema.

Overall, the diagnosis of bradykinic angioedema under ACE inhibitor or sartan is difficult to make because there is currently no rapid biological diagnostic method to identify them. Unpredictable, this AE is also at high risk of asphyxia in the event of laryngeal location.

The association with gliptins increases the risk of developing bradykinic AE. The appearance of bradykinic angioedema in a patient treated with ACE inhibitor or ARB II must therefore lead to immediate discontinuation of the drug and its contraindication for life.

Pregnancy

AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information**

When pregnancy is diagnosed, treatment with AIIRA should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).

Dual blockade of the renin-angiotensin-aldosterone system (RAAS)

There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).

If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.

Hydrochlorothiazide

Hypotension and electrolyte/fluid imbalance

As with all antihypertensive therapy, symptomatic hypotension may occur in some patients. Patients should be observed for clinical signs of fluid or electrolyte imbalance, e.g., volume depletion, hyponatraemia, hypochloremic alkalosis, hypomagnesaemia or hypokalaemia which may occur during intercurrent diarrhoea or vomiting. Periodic determination of serum electrolytes should be performed at appropriate intervals in such patients. Dilutional hyponatraemia may occur in oedematous patients in hot weather.

Metabolic and endocrine effects

Thiazide therapy may impair glucose tolerance. Dosage adjustment of antidiabetic agents, including insulin, may be required (see section 4.5). Latent diabetes mellitus may become manifest during thiazide therapy.

Thiazides may decrease urinary calcium excretion and may cause intermittent and slight elevation of serum calcium. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism.

Thiazides should be discontinued before carrying out tests for parathyroid function.

Increase in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy.

Thiazide therapy may precipitate hyperuricaemia and/or gout in certain patients. Because losartan potassium decreases uric acid, losartan potassium in combination with hydrochlorothiazide attenuates the diuretic-induced hyperuricaemia.

Hepatic impairment

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, as it may cause intrahepatic cholestasis, and since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

CO-VIZARTAN is contraindicated for patients with severe hepatic impairment (see section 4.3 and 5.2).

Other

In patients receiving thiazides, hypersensitivity reactions may occur with or without a history of allergy or bronchial asthma. Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazides.

Patients taking hydrochlorothiazide alone or in combination with other medications should be informed of the risk of non-melanoma skin cancer and the need to check their skin regularly for new lesions or modification of existing lesions and to report any suspicious skin lesions.

Suspicious skin lesions should be examined. Biopsy may be necessary for histological diagnosis.

To reduce the risk of skin cancer, patients will be advised to limit exposure to the sun and UV rays and to have adequate protection in case of sun exposure.

The use of hydrochlorothiazide should also be carefully reviewed in patients with a history of skin cancer.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information**Excipient

This medicine contains lactose. Its use is not recommended in patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary diseases).

Anti-doping test

This specialty contains hydrochlorothiazide, an active ingredient that can induce a positive reaction in tests carried out during anti-doping controls.

4.5 Interaction with other medicinal products and other forms of interaction**Losartan potassium**

Rifampicin and fluconazole have been reported to reduce levels of active metabolite. The clinical consequences of these interactions have not been evaluated.

As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium that may increase serum potassium (e.g., trimethoprim-containing products) may lead to increases in serum potassium. Co-medication is not advisable.

As with other medicines which affect the excretion of sodium, lithium excretion may be reduced. Therefore, serum lithium levels should be monitored carefully if lithium salts are to be co-administered with angiotensin II receptor antagonists.

When angiotensin II antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid at anti-inflammatory doses and nonselective NSAIDs), attenuation of the antihypertensive effect may occur.

Concomitant use of angiotensin II antagonists or diuretics and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor preexisting renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated, and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.

In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, the co-administration of angiotensin II receptor antagonists may result in a further deterioration of renal function. These effects are usually reversible.

Clinical trial data have shown dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia, and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).

Other substances inducing hypotension like tricyclic antidepressants, antipsychotics, baclofen, amifostine: Concomitant use with these drugs that lower blood pressure, as main or side-effect, may increase the risk of hypotension.

Gliptins (Sitagliptin, Vildagliptin, Linagliptin, Alogliptin, Saxagliptin) :

The combination of losartan with certain medications increasing the concentration of bradykinin, notably inhibitors of dipeptidyl peptidase IV (gliptin family), increases the risk of developing bradykin angioedema.

Hydrochlorothiazide

When given concurrently, the following drugs may interact with thiazide diuretics:

Alcohol, barbiturates, narcotics or antidepressants:

Potential of orthostatic hypotension may occur.

Antidiabetic drugs (oral agents and insulin):

The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the antidiabetic drug may be required. Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information**Other antihypertensive drugsAdditive effect.*Cholestyramine and colestipol resins:*

Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

Corticosteroids, ACTH

Intensified electrolyte depletion, particularly hypokalemia.

Pressor amines (e.g., adrenaline)

Possible decreased response to pressor amines but not sufficient to preclude their use.

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)

Possible increased responsiveness to the muscle relaxant.

Lithium

Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity: concomitant use is not recommended.

Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)

Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to allopurinol.

Anticholinergic agents (e.g. atropine, biperiden)

Increase of the bioavailability to thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.

Cytotoxic agents (e.g. cyclophosphamide, methotrexate)

Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.

Salicylates

In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the salicylates on the central nervous system.

Methyldopa

There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.

Cyclosporin

Concomitant treatment with cyclosporin may increase the risk of hyperuricaemia and gout-type complications.

Digitalis glycosides

Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias.

Medicinal products affected by serum potassium disturbances

Periodic monitoring of serum potassium and ECG is recommended when Losartan potassium/ Hydrochlorothiazide is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes:

- Class Ia antiarrhythmics (e.g. quinidine, hydroquinidine, disopyramide).
- Class III antiarrhythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide).
- Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).
- Others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, terfenadine, vincamine IV).

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information***Calcium salts*

Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements must be prescribed, serum calcium levels should be monitored, and calcium dosage should be adjusted accordingly.

Laboratory Test Interactions

Because of their effects on calcium metabolism, thiazides may interfere with tests for parathyroid function (see section 4.4).

Carbamazepine

Risk of symptomatic hyponatremia. Clinical and biological monitoring is required.

Iodine Contrast Media

In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of the iodine product. Patients should be rehydrated before the administration.

Amphotericin B (parenteral), corticosteroids, ACTH, stimulant laxatives or glycyrrhizin (found in liquorice):

Hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalaemia.

4.6 Pregnancy, Breastfeeding and Fertility**Pregnancy***Angiotensin II Receptor Antagonists (AIIRAs):*

The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.

Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3).

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

Hydrochlorothiazide

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.

Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during second and third trimesters may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.

Hydrochlorothiazide should not be used for essential hypertension in pregnant women, except in rare situations where no other alternative treatment could be used.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information****Breastfeeding**

Angiotensin II Receptor Antagonists (AIIARs):

Losartan:

Because no information is available regarding the use of CO-VIZARTAN during breast-feeding, CO-VIZARTAN are not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Hydrochlorothiazide:

Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production. The use of CO-VIZARTAN during breast-feeding is not recommended. If CO-VIZARTAN are used during breast-feeding, doses should be kept as low as possible.

4.7 Effects on ability to drive and use machines

No studies on the reactions on the ability to drive and use machines have been performed.

However, when driving vehicles or operating machinery it must be borne in mind that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy, in particular during initiation of treatment or when the dose is increased.

4.8 Undesirable effects

The adverse reactions below are classified where appropriate by system organ class and frequency according to the following convention:

Very common ($\geq 1/10$); Common ($\geq 1/100$, $< 1/10$); Uncommon ($\geq 1/1,000$, $< 1/100$); Rare ($\geq 1/10,000$, $< 1/1,000$); Very rare ($\leq 1/10,000$); Not known (cannot be estimated from the available data).

In clinical trials with losartan and hydrochlorothiazide, no adverse reactions peculiar to this combination of substances were observed. The adverse reactions were restricted to those which were formerly observed with losartan and/or hydrochlorothiazide.

In controlled clinical trials for essential hypertension, dizziness was the only adverse reaction reported as substance-related that occurred with an incidence greater than placebo in 1% or more of patients treated with losartan potassium and hydrochlorothiazide.

Next to these effects, there are further adverse reactions reported after the introduction:

System organ class	Adverse reaction	Frequency
Hepato-biliary disorders	Hepatitis	Rare
Investigations	Hyperkalaemia, elevation of ALT	Rare

The adverse reactions that have been seen with one of the individual components and may be potential adverse reactions with Losartan potassium/Hydrochlorothiazide are the following:

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets
2.3.3. Product Information
Losartan:

The following adverse reactions have been reported for losartan in clinical studies and in post-marketing experience:

System organ class	Adverse reaction	Frequency
Blood and lymphatic system disorders	Anaemia, purpura, ecchymosis, haemolysis	Uncommon
	Thrombocytopenia	Not known
Cardiac disorders	Hypotension, orthostatic hypotension, sternalgia, angina pectoris, grade II-AV block, cerebrovascular event, myocardial infarction, palpitation, arrhythmias (atrial fibrillations, sinus bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation)	Uncommon
Ear and labyrinth disorders	tigo, tinnitus	Uncommon
Eye disorders	Blurred vision, burning/stinging in the eye, conjunctivitis, decrease in visual acuity	Uncommon
Gastrointestinal disorders	Abdominal pain, nausea, diarrhoea, dyspepsia	Common
	Constipation, dental pain, dry mouth, flatulence, gastritis, vomiting, obstipation	Uncommon
	Pancreatitis	Not known
General disorders and administration site conditions	Asthenia, fatigue, chest pain	Common
	Fever, facial oedema, oedema	Uncommon
	Flu-like symptoms, malaise	Not known
Hepato-biliary disorders	Liver function abnormalities	Not known
Immune system disorders	Hypersensitivity: anaphylactic reactions, angioedema including swelling of the larynx and glottis causing airway obstruction and/or swelling of the face, lips, pharynx, and /or tongue; in some of these patients angioedema had been reported in the past in connection with the administration of other medicines, including ACE inhibitors.	Rare
Metabolism and nutrition disorders	Anorexia, gout	Uncommon
Musculoskeletal and connective tissue disorders	Muscle cramp, back pain, leg pain, myalgia	Commun
	Arm pain, joint swelling, knee pain, musculoskeletal pain, shoulder pain, stiffness, arthralgia, arthritis, coxalgia, fibromyalgia, muscle weakness	Uncommon
	Rhabdomyolysis	Not known
Nervous system disorders	Headache, dizziness	Common
	Nervousness, paraesthesia, peripheral neuropathy, tremor, migraine, syncope	Uncommon
	Dysgeusia	Not known
Psychiatric disorders	Insomnia	Common
	Anxiety, anxiety disorder, panic disorder, confusion, depression, abnormal dreams, sleep disorder, somnolence, memory impairment	Uncommon
Renal and urinary	Renal impairment, renal failure	Common
	nocturia, urinary frequency, urinary tract infection	Uncommon
Reproductive system and breast disorders	decreased libido, erectile dysfunction/impotence	Uncommon

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets
2.3.3. Product Information

Respiratory, thoracic and mediastinal disorders	cough, upper respiratory infection, nasal congestion, sinusitis, sinus disorder	Common
	Pharyngeal discomfort, pharyngitis, laryngitis, dyspnoea, bronchitis, epistaxis, rhinitis, respiratory congestion	Uncommon
Skin and subcutaneous tissue disorders	Alopecia, dermatitis, dry skin, erythema, flushing, photosensitivity, pruritus, rash, urticaria, sweating	Uncommon
Vascular disorders	Vasculitis	Uncommon
	Dose-related orthostatic effects	Not known
Investigations	Hyperkalaemia, mild reduction of haematocrit and haemoglobin, hypoglycaemia	Common
	Mild increase in urea and creatinine serum levels	Uncommon
	Increase in hepatic enzymes and bilirubin.	Very rare
	Hyponatraemia	Not known

Bradykinin angioedema has been reported in patients treated with angiotensin-converting enzyme inhibitors (ACE inhibitors) as well as angiotensin II receptor antagonists (IIARs) and gliptins. These angioedemas can have serious consequences.

Hydrochlorothiazide:

System organ class	Adverse reaction	Frequency
Blood and lymphatic system disorders	Agranulocytosis, aplastic anaemia, haemolytic anaemia, leukopenia, purpura, thrombocytopenia	Uncommon
Immune system disorders	Anaphylactic reaction	rare
Metabolism and nutrition disorders	Anorexia, hyperglycaemia, hyperuricaemia, hypokalaemia, hyponatraemia	Uncommon
Psychiatric disorders	Insomnia	Uncommon
Nervous system disorders	Cephalalgia	Common
Eye disorders	Transient blurred vision, xanthopsia	Uncommon
Vascular disorders	Necrotising angitis (vasculitis, cutaneous vasculitis)	Uncommon
Respiratory, thoracic and mediastinal disorders	Respiratory distress including pneumonitis and pulmonary oedema	Uncommon
Gastrointestinal disorders	Sialadenitis, spasms, stomach irritation, nausea, vomiting, diarrhoea, constipation	Uncommon
Hepato-biliary disorders	Icterus (intrahepatic cholestasis), pancreatitis	Uncommon
Skin and subcutaneous tissue disorders	Photosensitivity, urticaria, toxic epidermal necrolysis	Uncommon
	Cutaneous lupus erythematosus	Not known
Musculoskeletal and connective tissue disorders	Muscle cramps	Uncommon
Renal and urinary disorders	Glycosuria, interstitial nephritis, renal dysfunction, renal failure	Uncommon
General disorders and administration site conditions	Fever, dizziness	Uncommon

Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at the regional pharmacovigilance center.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information****4.9 Overdose**

No specific information is available on the treatment of overdosage with CO-VIZARTAN. Treatment is symptomatic. Therapy with CO-VIZARTAN should be discontinued and the patient observed closely. Suggested measures include induction of emesis if ingestion is recent, and correction of dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures.

Losartan

Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.

Neither losartan potassium nor the active metabolite can be removed by haemodialysis.

Hydrochlorothiazide

The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalaemia, hyponatraemia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalaemia may accentuate cardiac arrhythmias.

The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.

5. Pharmacological properties**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Angiotensin II- antagonists and diuretics

ATC code: C09DA01

Losartan / Hydrochlorothiazide

The components of CO-VIZARTAN have been shown to have an additive effect on blood pressure reduction, reducing blood pressure to a greater degree than either component alone. This effect is thought to be a result of the complimentary actions of both components. Further, as a result of its diuretic effect, hydrochlorothiazide increases plasma renin activity, increases aldosterone secretion, decreases serum potassium, and increases the levels of angiotensin II. Administration of losartan potassium blocks all the physiologically relevant actions of angiotensin II and through inhibition of aldosterone could tend to attenuate the potassium loss associated with the diuretic.

Losartan has been shown to have a mild and transient uricosuric effect. Hydrochlorothiazide has been shown to cause modest increases in uric acid, the combination of losartan potassium and hydrochlorothiazide tend to attenuate the diuretic-induced hyperuricemia.

The antihypertensive effect of CO-VIZARTAN is sustained for a 24-hour period. In clinical studies of at least one year's duration, the antihypertensive effect was maintained with continued therapy. Despite the significant decrease in blood pressure, administration of CO-VIZARTAN had no clinically significant effect on heart rate. In clinical trials, after 12 weeks of therapy with Losartan 50mg/Hydrochlorothiazide 12.5 mg, trough sitting diastolic blood pressure was reduced by an average of up to 13.2 mmHg.

CO-VIZARTAN is effective in reducing blood pressure in males and females, blacks and non-blacks and in younger (<65 years) and older (≥65 years) patients and is effective in all degrees of hypertension.

Losartan

Losartan is a synthetically produced oral angiotensin-II receptor (type AT₁) antagonist. Angiotensin II, a potent vasoconstrictor, is the primary active hormone of the renin angiotensin system and an important determinant of the pathophysiology of hypertension. Angiotensin II binds to the AT₁ receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland, kidneys and the heart) and elicits several important biological actions, including vasoconstriction and the release of aldosterone. Angiotensin II also stimulates smooth muscle cell proliferation.

Losartan selectively blocks the AT₁ receptor. In vitro and in vivo losartan potassium and its pharmacologically active carboxylic acid metabolite E- 3174 block all physiologically relevant actions of angiotensin II, regardless of the source or route of its synthesis.

Losartan does not have an agonist effect nor does it block other hormone receptors or ion channels important in cardiovascular regulation. Furthermore, losartan potassium does not inhibit ACE (kininase II), the enzyme that degrades bradykinin. Consequently, there is thus no increase in bradykinin-mediated undesirable effects.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information**

During the administration of losartan, the removal of the angiotensin II negative feedback on renin secretion leads to increased plasma-renin activity (PRA).

Increase in the PRA leads to an increase in angiotensin II in plasma. Despite these increases, antihypertensive activity and suppression of the plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade.

After the discontinuation of losartan potassium, PRA and angiotensin II values fell within 3 days to the baseline values.

Both losartan and its principal active metabolite have a far greater affinity for the AT1 receptor than for the AT2 receptor.

The active metabolite is 10- to 40-times more active than Losartan potassium on a weight for weight basis.

In a study specifically designed to assess the incidence of cough in patients treated with losartan as compared to patients treated with ACE inhibitors, the incidence of cough reported by patients receiving losartan or hydrochlorothiazide was similar and was significantly less than in patients treated with an ACE inhibitor. In addition, in an overall analysis of 16 double-blind clinical trials in 4131 patients, the incidence of spontaneously reported cough in patients treated with losartan potassium was similar (3.1%) to that of patients treated with placebo (2.6%) or hydrochlorothiazide (4.1%), whereas the incidence with ACE inhibitors was 8.8%.

In nondiabetic hypertensive patients with proteinuria, the administration of losartan potassium significantly reduces proteinuria, fractional excretion of albumin and IgG.

Losartan maintains glomerular filtration rate and reduces filtration fraction.

Generally, losartan causes a decrease in serum uric acid (usually <0.4 mg/dL) which was persistent in chronic therapy.

Losartan potassium has no effect on autonomic reflexes and no sustained effect on plasma norepinephrine.

In patients with left ventricular failure, 25 mg and 50 mg doses of Losartan potassium produced positive hemodynamic and neurohormonal effects characterized by an increase in cardiac index and decreases in pulmonary capillary wedge pressure, systemic vascular resistance, mean systemic arterial pressure and heart rate and a reduction in circulating levels of aldosterone and norepinephrine, respectively. The occurrence of hypotension was dose related in these heart failure patients.

Hypertension Studies

In controlled clinical studies, once-daily administration of losartan to patients with mild to moderate essential hypertension produced statistically significant reductions in systolic and diastolic blood pressure. Measurement of blood pressure 24 hours post-dose relative to 5-6 hours post-dose demonstrated blood pressure reduction over 24 hours; the natural diurnal rhythm was retained. Blood pressure reduction at the end of the dosing interval was 70 – 80 % of the effect seen 5-6 hours post-dose.

Discontinuation of losartan in hypertensive patients did not result in an abrupt rise in blood pressure (rebound). Despite the marked decrease in blood pressure, losartan had no clinically significant effect on heart rate.

Losartan is equally effective in males and females, and in younger (below the age of 65 years) and older hypertensive patients.

LIFE Study

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was a randomised, triple-blind, active-controlled study in 9193 hypertensive patients aged 55 to 80 years with ECG-documented left ventricular hypertrophy.

Patients were randomised to once daily losartan potassium 50 mg or once daily atenolol 50 mg. If goal blood pressure (<140/90 mmHg) was not reached, hydrochlorothiazide (12.5 mg) was added first and, if needed, the dose of losartan potassium or atenolol was then increased to 100 mg once daily. Other antihypertensives, with the exception of ACE inhibitors, angiotensin II antagonists or beta-blockers were added if necessary, to reach the goal blood pressure.

The mean length of follow up was 4,8 years.

The primary endpoint was the composite of cardiovascular morbidity and mortality as measured by a reduction in the combined incidence of cardiovascular death, stroke and myocardial infarction. Blood pressure was significantly lowered to similar levels in the two groups.

Treatment with losartan resulted in a 13.0% risk reduction ($p=0.021$, 95 % confidence interval 0.77-0.98) compared with atenolol for patients reaching the primary composite endpoint. This was mainly attributable to a reduction of the incidence of stroke. Treatment with losartan potassium reduced the risk of stroke by 25% relative to atenolol ($p=0.001$, 95% confidence interval 0.63- 0.89). The rates of cardiovascular death and myocardial infarction were not significantly different between the 2 groups.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information****Dual blockade of the renin-angiotensin-aldosterone system (RAAS)**

Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.

ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of endorgan damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.

These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.

ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.

ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.

The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.

Hydrochlorothiazide

Hydrochlorothiazide is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss and decrease in serum potassium. The renin-aldosterone link is mediated by angiotensin II and therefore co-administration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics.

After oral use, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours; the antihypertensive effect persists for up to 24 hours.

5.2 Pharmacokinetic properties**Absorption****Losartan**

Following oral administration, losartan is well absorbed and undergoes first-pass metabolism, forming an active carboxylic acid metabolite and other inactive metabolites. The systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. There was no clinically significant effect on the plasma concentration profile of losartan when the drug was administered with a standardized meal.

Distribution**Losartan**

Both losartan and its active metabolite are $\geq 99\%$ bound to plasma proteins, primarily albumin. The volume of distribution of losartan is 34 litres. Studies in rats indicate that Losartan crosses the blood-brain barrier poorly, if at all.

Hydrochlorothiazide

Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Biotransformation**Losartan**

About 14% of an intravenously- or orally administered dose of losartan potassium is converted to its active metabolite. Following oral and intravenous administration of ^{14}C -labelled losartan, circulating plasma radioactivity primarily is

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information**

attributed to losartan and its active metabolite. Minimal conversion of losartan to its active metabolite was seen in about one percent of individuals studied.

In addition to the active metabolite, inactive metabolites are formed, including two major metabolites formed by hydroxylation of the butyl side chain and a minor metabolite, an N-2 tetrazole glucuronide.

Elimination**Losartan potassium**

Plasma clearance of losartan and its active metabolite is about 600 mL/min and 50 mL/min, respectively. Renal clearance of losartan and its active metabolite is about 74 mL/min and 26 mL/min, respectively. When losartan is administered orally, about 4% of the dose is excreted unchanged in the urine, and about 6% of the dose is excreted in the urine as active metabolite. The pharmacokinetics of losartan potassium and its active metabolite are linear with oral losartan potassium doses up to 200 mg.

Following oral administration, plasma concentrations of losartan and its active metabolite declines polyexponentially with a terminal half-life of about 2 hours and 6-9 hours, respectively. During once-daily dosing with 100 mg, neither losartan nor its active metabolite accumulates significantly in plasma.

Both biliary and urinary excretion contribute to the elimination of losartan and its metabolites. Following an oral dose of ¹⁴C-labelled losartan potassium in man, about 35% of radioactivity is recovered in the urine and 58% in the faeces.

Hydrochlorothiazide

Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5,6 and 14,8 hours. At least 61 percent of the oral dose is eliminated unchanged within 24 hours.

Characteristics in Patients**Losartan / Hydrochlorothiazide**

The plasma concentrations of losartan and its active metabolite and the absorption of hydrochlorothiazide in elderly hypertensives are not significantly different from those in young hypertensives.

Losartan

Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan potassium and its active metabolite were, respectively, 5-fold and 17-fold greater than those seen in young male volunteers.

Pharmacokinetic studies showed that the AUC of losartan potassium in Japanese and non-Japanese healthy male subjects is not different. However, the AUC of the carboxylic acid metabolite (E-3174) appears to be difference between the two groups, with an approximately 1.5-fold higher exposure in Japanese subjects than in non-Japanese subjects. The clinical significance of these results is not known. Neither losartan nor the active metabolite can be removed by haemodialysis.

5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, genotoxicity and carcinogenic potential. The toxic potential of the combination of losartan / hydrochlorothiazide was evaluated in chronic toxicity studies for up to six months duration in rats and dogs after oral administration, and the changes observed in these studies with the combination were mainly produced by the losartan component. The administration of the losartan / hydrochlorothiazide combination induced a decrease in the red blood cell parameters (erythrocytes, haemoglobin, haematocrit), a rise in urea-N in the serum, a decrease in heart weight (without a histological correlate) and gastrointestinal changes (mucous membrane lesions, ulcers, erosions, haemorrhages).

There was no evidence of teratogenicity in rats or rabbits treated with the losartan potassium/ hydrochlorothiazide combination. Foetal toxicity in rats, as evidenced by a slight increase in supernumerary ribs in the F1 generation, was observed when females were treated prior to and throughout gestation. As observed in studies with losartan potassium alone, adverse foetal and neonatal reactions, including renal toxicity and foetal death, occurred when pregnant rats were treated with the losartan / hydrochlorothiazide combination during late gestation and/or lactation.

CO-VIZARTAN® 50 mg/12,5 mg Film-coated tablets**2.3.3. Product Information****6. Pharmaceutical particulars****6.1 List of excipients**Core:

Microcrystalline Cellulose
Pregelatinized Starch Maize
Lactose
Magnesium Stearate

Film-coating:

Opadry Yellow 20A52067
Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months.

6.4 Special precautions for storage

Do not store above 30°C. Store in the original package

6.5 Nature and contents of container

Blister of PVC/PVDC/ALU pack of 14 & 28.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MARKETING AUTHORISATION HOLDER AND MANUFACTURING SITE ADDRESS

- Marketing Authorization holder:

COOPER PHARMA

41, Rue Mohamed DIOURI, 20110 Casablanca
Morocco

- Manufacturing, Control, Packaging site & batch release site:

COOPER PHARMA

Route 107, Km 2.5 Douar Oulad Sidi Abbou
Tit Mellil Casablanca
Morocco

8. MARKETING AUTHORISATION NUMBER

20/4369/DGC&PHS/2018.

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorization: 06 June 2018.

10. DATE OF REVISION OF THE TEXT

February 2020.

PRESCRIPTION AND DELIVERY CONDITIONS

Table A (list I).